Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - Raymond (NSE:RYMD) James has reiterated its Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), currently trading at $12.08, following the company’s presentations at the American Society of Retina Specialists annual meeting (ASRS 2025). According to InvestingPro data, analyst targets range from $14 to $22, reflecting significant potential upside from current levels.
The firm highlighted Ocular Therapeutix’s encore analyses for Axpaxli in non-proliferative diabetic retinopathy (NPDR), noting that while these results were previously presented, they provide an opportunity to reassess Axpaxli’s potential in this indication and diabetic macular edema (DME).
Raymond James acknowledged that the primary focus for both Ocular Therapeutix and investors remains the SOL-1 readout expected in the first quarter of 2026 for wet age-related macular degeneration (wAMD).
The research firm does not currently include NPDR revenues for Axpaxli in its financial model but views diabetic retinopathy as a significant opportunity with over one million moderate to severe NPDR patients in the U.S., most of whom are currently untreated.
Raymond James noted its perspective on Axpaxli in NPDR has evolved from initial skepticism following the first HELIOS data disclosure to a "cautiously constructive" view, based on further data maturity and consistent anatomic improvements observed in patients.
In other recent news, Ocular Therapeutix reported its first-quarter 2025 earnings, revealing a revenue of $10.6 million, which fell short of analyst expectations of $17.4 million. The company also posted a diluted earnings per share of $(0.38), below the projected $(0.30). The revenue decline was linked to factors such as pricing adjustments and changes in stocking patterns for its product Dextenza. Despite these results, several analyst firms have maintained positive ratings on the stock. H.C. Wainwright reaffirmed a Buy rating with a $15 price target, while Clear Street also maintained a Buy rating, setting a target at $18. Raymond James reiterated a Strong Buy rating with a price target of $19, noting the company’s progress in clinical trials. Ocular Therapeutix announced it would conclude patient enrollment for the SOL-R trial ahead of schedule, showcasing effective management of clinical trials. The U.S. FDA has indicated that results from the SOL-1 and SOL-R trials could support a potential New Drug Application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.